{"id":"eltrombopag-epag","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Thromboembolic events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eltrombopag is a small-molecule, orally bioavailable TPO receptor agonist that mimics the action of endogenous thrombopoietin. By activating the TPO receptor (also known as c-Mpl) on megakaryocyte progenitor cells in the bone marrow, it promotes megakaryocyte proliferation and differentiation, leading to increased platelet production. This mechanism makes it useful in conditions characterized by thrombocytopenia (low platelet counts).","oneSentence":"Eltrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:07.980Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic immune thrombocytopenia (ITP)"},{"name":"Thrombocytopenia associated with chronic hepatitis C"},{"name":"Severe aplastic anemia"}]},"trialDetails":[{"nctId":"NCT07476846","phase":"NA","title":"rhTPO Dose Escalation vs Eltrombopag Switch in ITP","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":112},{"nctId":"NCT04304820","phase":"PHASE2","title":"Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2020-05-07","conditions":"Severe Aplastic Anemia","enrollment":80},{"nctId":"NCT07189910","phase":"PHASE4","title":"Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-12-01","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":150},{"nctId":"NCT06630221","phase":"PHASE2","title":"Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations","status":"RECRUITING","sponsor":"Abhay Singh, MD MPH","startDate":"2025-06-17","conditions":"Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia","enrollment":25},{"nctId":"NCT06834451","phase":"PHASE4","title":"Bioequivalence Study of Revolade® Eltrombopag 50 mg","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centro de Atencion e Investigacion Medica","startDate":"2025-06-01","conditions":"Healthy, Healthy Donors","enrollment":30},{"nctId":"NCT07001397","phase":"PHASE3","title":"Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-06-23","conditions":"Aplastic Anemias","enrollment":70},{"nctId":"NCT04269889","phase":"PHASE1, PHASE2","title":"Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2020-12-01","conditions":"Anemia, Diamond-Blackfan","enrollment":15},{"nctId":"NCT01623167","phase":"PHASE1, PHASE2","title":"Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2012-07-02","conditions":"Severe Aplastic Anemia","enrollment":207},{"nctId":"NCT02446145","phase":"PHASE2","title":"A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients","status":"TERMINATED","sponsor":"Technische Universität Dresden","startDate":"2015-05","conditions":"Acute Myeloid Leukemia","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Promacta"],"phase":"marketed","status":"active","brandName":"Eltrombopag (EPAG)","genericName":"Eltrombopag (EPAG)","companyName":"Centro de Atencion e Investigacion Medica","companyId":"centro-de-atencion-e-investigacion-medica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eltrombopag is a small molecule that acts as a thrombopoietin receptor agonist. It is used to treat various conditions including Acute Myeloid Leukemia, Severe Aplastic Anemia, and Aplastic Anemias.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}